Update on the optimal management of patients with colorectal liver metastases

Critical Reviews in Oncology/Hematology

Volumn 84, Issue 1, 2012, Pages 59-70

  Alberts, Steven R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Ablation; Bevacizumab; Cetuximab; Colorectal cancer liver metastases; Hepatic arterial infusion; Portal vein embolization; Stereotactic body radiotherapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; PLACEBO; YTTRIUM 90;

ADJUVANT THERAPY; ARTIFICIAL EMBOLISM; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; COLORECTAL CANCER; COLORECTAL LIVER METASTASIS; DRUG DOSE REDUCTION; DRUG HALF LIFE; FATTY LIVER; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; LIVER INJURY; LIVER METASTASIS; LIVER SURGERY; LIVER VENOOCCLUSIVE DISEASE; MICROWAVE THERAPY; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); RADIOFREQUENCY ABLATION; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SELECTIVE INTERNAL RADIATION THERAPY; STEREOTACTIC BODY RADIATION THERAPY; SYSTEMATIC REVIEW;

COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY;

EID: 84866487024     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.02.007     Document Type: Review

References (89)

1. Siegel R., Ward E., Brawley O., Jemal A. The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011, 61:212-236. Cancer statistics.
2. Manfredi S., Lepage C., Hatem C., et al. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 2006, 244:254-259.
3. Manfredi S., Bouvier A.M., Lepage C., Coatmeur O., Faivre J., Bouvier A.M. Incidence and patterns of recurrence after resection for cure of colonic cancer in a well defined population. Br J Surg 2006, 93:1115-1122.
4. Steele G., Bleday R., Mayer R.J., Lindblad A., Petrelli N., Weaver D. A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal Tumor Study Group protocol 6584. J Clin Oncol 1991, 9:1105-1112.
5. Choti M.A., Sitzmann J.V., Tiburi M.F., et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002, 235:759-766.
6. Pawlik T.M., Scoggins C.R., Zorzi D., et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 2005, 241:715-722.
7. Gomez D., Cameron I.C. Prognostic scores for colorectal liver metastasis: clinically important or an academic exercise?. HPB (Oxford) 2010, 12:227-238.
8. Ayez N., Lalmahomed Z.S., van der Pool A.E., et al. Is the clinical risk score for patients with colorectal liver metastases still useable in the era of effective neoadjuvant chemotherapy?. Ann Surg Oncol 2011, 18:2757-2763.
9. Abdalla E.K. Resection of colorectal liver metastases. J Gastrointest Surg 2011, 15:416-419.
10. Benson A.B., Arnoletti J.P., Bekaii-Saab T., et al. NCCN clinical practice guidelines in oncology,™Colon cancer V. 3. 2011. J Natl Compr Cancer Netw 2011, 9:1238-1290.
11. Abdalla E.K., Vauthey J.N., Ellis L.M., et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004, 239:818-825.
12. Gleisneer A.L., Choti M.A., Assumpcao L., Nathan H., Schulick R.D., Pawlik T.M. Colorectal liver metastases: recurrence and survival following hepatic resection, radiofrequency ablation, and combined resection-radiofrequency ablation. Arch Surg 2008, 143:1204-1212.
13. Aloia T.A., Vauthey J.N., Loyer E.M., et al. Solitary colorectal liver metastasis: resection determines outcome. Arch Surg 2006, 141:460-466.
14. de Jong M.C., Pulitano C., Ribero D., et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg 2009, 250:440-448.
15. Zorzi D., Mullen J.T., Abdalla E.K., et al. Comparison between hepatic wedge resection and anatomic resection for colorectal liver metastases. J Gastrointest Surg 2006, 10:86-94.
16. Martin R., Paty P., Fong Y., et al. Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. J Am Coll Surg 2003, 197:233-241.
17. Lyass S., Zamir G., Matot I., Goitein D., Eid A., Jurim O. Combined colon and hepatic resection for synchronous colorecal liver metastases. J Surg Oncol 2001, 78:17-21.
18. Chua H.K., Sondenaa K., Tsiotos G.G., Larson D.R., Wolff B.G., Nagorney D.M. Concurrent vs. staged colectomy and hepatectomy for primary colorectal cancer with synchronous hepatic metastases. Dis Colon Rectum 2004, 47:1310-1316.
19. Reddy S.K., Pawlik T.M., Zorzi D., et al. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol 2007, 14:3481-3491.
20. Mentha G., Majno P.E., Andres A., Rubbia-Brandt L., Morel P., Roth A.D. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg 2006, 93:872-878.
21. Aloia T.A., Fahy B.N. A decision analysis model predicts the optimal treatment pathway for patients with colorectal cancer and resectable synchronous liver metastases. Clin Colorectal Cancer 2008, 7:197-201.
22. Abdalla E.K. Portal vein embolization (prior to major hepatectomy) effects on regeneration, resectability, and outcome. J Surg Oncol 2010, 102:960-967.
23. Abulkhir A., Limongelli P., Healey A.J., et al. Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann Surg 2008, 247:49-57.
24. Azoulay D., Castaing D., Smail A., et al. Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization. Ann Surg 2000, 231:480-486.
25. Abdalla E.K., Barnett C.C., Doherty D., Curley S.A., Vauthey J.-N. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg 2002, 137:675-681.
26. Elias D., Ouellet J.F., De Baère T., Lasser P., Roche A. Preoperative selective portal vein embolization before hepatectomy for liver metastases: long-term results and impact on survival. Surgery 2002, 131:294-299.
27. Wicherts D.A., de Haas R.J., Andreani P., et al. Impact of portal vein embolization on long-term survival of patients with primarily unresectable colorectal liver metastases. Br J Surg 2010, 97:240-250.
28. Wong S.L., Mangu P.B., Choti M.A., et al. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 2010, 28:493-508.
29. Gibson T.B. Radiofrequency ablation for patients with colorectal cancer and unresectable liver metastasis. Clin Colorectal Cancer 2006, 5:318-320.
30. Reuter N.P., Woodall C.E., Scoggins C.R., McMasters K.M., Martin R.C. Radiofrequency ablation vs. resection for hepatic colorectal metastasis: therapeutically equivalent?. J Gastrointest Surg 2009, 13:486-491.
31. Hur H., Ko Y.T., Min B.S., et al. Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg 2009, 197:728-736.
32. Wright A.S., Sampson L.A., Warner T.F., Mahvi D.M., Lee F.T. Radiofrequency versus microwave ablation in a hepatic porcine model. Radiology 2005, 236:132-139.
33. Ogata Y., Uchida S., Hisaka T., et al. Intraoperative thermal ablation therapy for small colorectal metastases to the liver. Hepatogastroenterology 2008, 55:550-556.
34. Tanaka K., Shimada H., Nagano Y., Endo I., Sekido H., Togo S. Outcome after hepatic resection versus combined resection and microwave ablation for multiple bilobar colorectal metastases to the liver. Surgery 2006, 139:263-273.
35. Jagad R.B., Koshariya M., Kawamoto J., et al. Laparoscopic microwave ablation of liver tumors: our experience. Hepatogastroenterology 2008, 55:27-32.
36. Martin R.C., Scoggins C.R., McMasters K.M. Microwave hepatic ablation: initial experience of safety and efficacy. J Surg Oncol 2007, 96:481-486.
37. Shibata T., Niinobu T., Ogata N., Takami M. Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma. Cancer 2000, 89:276-284.
38. Liang P., Wang Y., Yu X., Dong B. Malignant liver tumors: treatment with percutaneous microwave ablation-complications among cohort of 1136 patients. Radiology 2009, 251:933-940.
39. de Jong M.C., Mayo S.C., Pulitano C., et al. Repeat curative intent liver surgery is safe and effective for recurrent colorectal liver metastasis: results from an international multi-institutional analysis. J Gastrointest Surg 2009, 13:2141-2151.
40. Brouquet A., Vauthey J.-N., Badgwell B.D., et al. Hepatectomy for recurrent colorectal liver metastases after radiofrequency ablation. Br J Surg 2011, 98:1003-1009.
41. Ahmadzadehfar H., Bersack H.-J., Ezziddin S. Radioembolization of liver tumors with yttrium-90 microspheres. Semin Nucl Med 2010, 40:105-121.
42. Mulcahy M.F., Lewandowski R.J., Ibrahim S.M., et al. Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer 2009, 115:1849-1858.
43. Kennedy A.S., Coldwell D., Nutting C., et al. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 2006, 65:412-425.
44. Jakobs T.F., Hoffmann R.T., Dehm K., et al. Hepatic yttrium-90 chemoembolization of chemotherapy-refractory colorectal cancer liver metastases. J Vasc Interv Radio 2008, 19:1187-1195.
45. Cianni R., Urigo C., Notarianni E., et al. Selective internal radiation therapy with SIR-spheres for the treatment of unresectable colorectal hepatic metastases. Cardiovasc Intervent Radiol 2009, 32:1179-1186.
46. Hong K., McBride J.D., Georgiades C.S., et al. Salvage therapy for liver-dominant colorectal liver metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization. J Vasc Interv Radiol 2009, 20:360-367.
47. Omed A., Lawrance J.A.L., Murphy G., et al. A retrospective analysis of selective internal radiation therapy (SIRT) with yttrium-90 microspheres in patients with unresectable hepatic malignancies. Clin Radiol 2010, 65:720-728.
48. Sharma R.A., Van Hazel G.A., Morgan B., et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 2007, 25:1099-1105.
49. Swaminath A., Dawson L.A. Emerging role of radiotherapy in the management of liver metastases. Cancer J 2010, 16:150-155.
50. Chang D.T., Swaminath A., Kozak M., et al. Stereotactic body radiography for colorectal liver metastases. A pooled analysis. Cancer 2011, 117:4060-4069.
51. Lee M.T., Kim J.J., Dinniwell R., et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 2009, 27:1585-1591.
52. Hoyer M., Roed H., Hansen A.T., et al. Phase II study on stereotactic body radiotherapy for colorectal metastases. Acta Oncol 2006, 45:823-830.
53. Pwint T.P., Midgley R., Kerr D.J. Regional hepatic chemotherapies in the treatment of colorectal cancer metastases to the liver. Semin Oncol 2010, 37:149-159.
54. Mocellin S., Pasquali S., Nitti D. Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer (review). Cochrane Database Syst Rev 2009, (3):CD007823.
55. Adam R., Pascal G., Castaing D., et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?. Ann Surg 2004, 240:1052-1061.
56. Nordlinger B., Sorbye H., Glimelius B., et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008, 371:1007-1016.
57. Mitry E., Fields A.L., Bleiberg H., et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008, 26:4906-4911.
58. Ychou M., Hohenberger W., Thezenas S., et al. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol 2009, 20:1964-1970.
59. Gruenberger B., Tamandl D., Schueller J., et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008, 26:1830-1835.
60. Folprecht G., Grothey A., Alberts S., Raab H.-R., Köhne C.-H. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005, 16:1311-1319.
61. Tournigand C., André T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004, 22:229-237.
62. Tournigand C., Cervantes A., Figer A., et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 2006, 24:394-400.
63. Alberts S.R., Horvath W.L., Sternfield W.C., et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 2005, 23:9243-9249.
64. De La Cámara J, Rodriguez J, Rotellar F, et al. Triplet therapy with oxaliplatin, irinotecan, 5-fluorouracil, and folinic acid with a combined modality approach in patients with liver metastases from colorectal cancer. J Clin Oncol 2004; 22(14S): abstract 3593. Proceedings of the 2004 ASCO Annual Meeting Proceedings; New Orleans, LA, 5-8 June; 2004.
65. Pozzo C., Basso M., Cassano A., et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004, 15:933-939.
66. Ho W.M., Ma B., Mok T., et al. Liver resection after irinotecan, 5-fluorouracil, and folinic cid for patients with unresectable colorectal liver metastases. Med Oncol 2005, 22:303-312.
67. Ychou M., Viret F., Kramar A., et al. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother Pharmacol 2008, 62:195-201.
68. Falcone A., Ricci S., Brunetti I., et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment of metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007, 25:1670-1676.
69. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
70. Saltz L.B., Clarke S., Diaz-Rubio E., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26:2013-2019.
71. Van Cutsem E., Köhne C.-H., Hitre E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360:1408-1417.
72. Van Cutsem E., Köhne C.-H., Láng I., et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011, 29:2011-2019.
73. Bokemeyer C., Bondarenko I., Hartmann J.T., et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011, 22:1535-1546.
74. Douillard J.-Y., Siena S., Cassidy J., et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010, 28:4697-4705.
75. Cassidy J, Cunningham D, Berry SR, Rivera F, Clarke SJ, Kretzschmar A, et al. Surgery with curative intent in patients (pts) treated with first-line chemotherapy (CT)+bevacizumab (BEV) for metastatic colorectal cancer (mCRC): First BEAT and NO16966. J Clin Oncol 2008; 26(suppl). Proceedings of the 2008 ASCO Annual Meeting; Chicago, IL, May 30 to June 3, 2008: abstract 4022 and presented poster.
76. Bertolini F., Malavasi N., Scarabelli L., et al. FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer. Br J Cancer 2011, 104:1079-1084.
77. Wong A., Cunningham D., Barbachano Y., et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol 2011, 22:2042-2048.
78. Köhne CH, Bokemeyer C, Heeger S, Rougier P, Van Cutsem E. Efficacy of chemotherapy+cetuximab according to metastatic site in KRAS wild-type metastatic colorectal cancer (mCRC): analysis of CRYSTAL and OPUS studies. Ann Oncol 2011; 22(suppl 5): v10. Proceedings of the 13th World Congress on Gastrointestinal Cancer; Barcelona, Spain; 22-25 June 2011: abstract O-0002 and presented slides.
79. Adam R., Aloia T., Lévi F., et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 2007, 25:4593-4602.
80. Folprecht G., Gruenberger T., Bechstein W.O., et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010, 11:38-47.
81. Maughan T.S., Adams R.A., Smith C.G., et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011, 377:2103-2114.
82. Tveit K, Guren T, Glimelius B, et al. Randomized phase III study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: the NORDIC VII study (NCT00145314). Ann Oncol 2010; 21(suppl 8): 9. Proceedings of the 35th ESMO Congress; Milan, Italy; 8-12 October, 2010: abstract LBA20 and presented slides.
83. Kneuertz P.J., Maithel S.K., Staley C.A., Kooby D.A. Chemotherapy-associated liver injury: impact on surgical management of colorectal liver metastases. Ann Surg Oncol 2011, 18:181-190.
84. Pessaux P., Chenard M.-P., Bachellier P., Jaeck D. Consequences of chemotherapy on resection of colorectal liver metastases. J Visceral Surg 2010, 147:e193-e201.
85. Ramadori G., Cameron S. Effects of systemic chemotherapy on the liver. Ann Hepatol 2010, 9:133-143.
86. Marsman H.A., Van Der Pool A.E., Verheij J., et al. Hepatic steatosis assessment with CT or MRI in patients with colorectal liver metastases after neoadjuvant chemotherapy. J Surg Oncol 2011, 104:10-16.
87. Nakano H., Oussoultzoglou E., Rosso E., et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 2008, 247:118-124.
88. Vauthey J.N., Pawlik T.M., Ribero D., et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006, 24:2065-2072.
89. Kishi Y., Zorzi D., Contreras C.M., et al. Extended postoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol 2010, 17:2870-2876.